Figures & data
Figure 1 Bone turnover marker (TRAP-5b, total-P1NP) levels. TRAP-5b and total-P1NP levels increased immediately following discontinuation of denosumab.
![Figure 1 Bone turnover marker (TRAP-5b, total-P1NP) levels. TRAP-5b and total-P1NP levels increased immediately following discontinuation of denosumab.](/cms/asset/da763308-b366-44e8-907f-233b3a700230/dcia_a_205971_f0001_b.jpg)
Figure 2 2D-BMD levels measured by DXA. DXA revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.
![Figure 2 2D-BMD levels measured by DXA. DXA revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.](/cms/asset/86d266cb-2170-44ee-b857-fa3282101eec/dcia_a_205971_f0002_b.jpg)
Figure 3 3D-BMD levels measured by QCT. QCT revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.
![Figure 3 3D-BMD levels measured by QCT. QCT revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.](/cms/asset/23b4a499-a3b6-4834-a794-4428c82a46ff/dcia_a_205971_f0003_b.jpg)
Figure 4 Cortical parameters of the hip measured by QCT. QCT revealed that the cortical parameter (cortical thickness and cortical BMD) decreased after discontinuation of denosumab treatment.
![Figure 4 Cortical parameters of the hip measured by QCT. QCT revealed that the cortical parameter (cortical thickness and cortical BMD) decreased after discontinuation of denosumab treatment.](/cms/asset/39944c93-6fe8-4f97-be15-0911702225a5/dcia_a_205971_f0004_b.jpg)
Figure 5 Biomechanical parameters of the hip measured by QCT. QCT revealed that the BR (index of cortical instability) increased and CSMI (index of bending strength) decreased after discontinuation of denosumab treatment.
![Figure 5 Biomechanical parameters of the hip measured by QCT. QCT revealed that the BR (index of cortical instability) increased and CSMI (index of bending strength) decreased after discontinuation of denosumab treatment.](/cms/asset/38afdf54-f9ae-4809-b3df-7ba5e324ba10/dcia_a_205971_f0005_b.jpg)